Figure 3.
Prevalence of grade ≥ 3 cytopenias before and after idecabtagene vicleucel (ide-cel) CAR-T therapy. Prevalence of grade ≥ 3 cytopenias at apheresis, day −5, day 30, day 60, and day 90. Grade 3 cytopenias: Anemia with hemoglobin < 8 g/dL; Neutropenia with absolute neutrophil count < 1000/μL; Thrombocytopenia with platelet trend < 50 000/μL.

Prevalence of grade ≥ 3 cytopenias before and after idecabtagene vicleucel (ide-cel) CAR-T therapy. Prevalence of grade ≥ 3 cytopenias at apheresis, day −5, day 30, day 60, and day 90. Grade 3 cytopenias: Anemia with hemoglobin < 8 g/dL; Neutropenia with absolute neutrophil count < 1000/μL; Thrombocytopenia with platelet trend < 50 000/μL.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal